Sulindac attenuates valproic acid-induced oxidative stress levels in primary cultured cortical neurons and ameliorates repetitive/stereotypic-like movement disorders in Wistar rats prenatally exposed to valproic acid

International Journal of Molecular Medicine

Volumn 35, Issue 1, 2015, Pages 263-270

  Zhang, Yinghua ^a,b   Yang, Cailing ^a   Yuan, Guoyan ^a   Wang, Zhongping ^b,c   Cui, Weigang ^a,b   Li, Ruixi ^b  

^a XINXIANG MEDICAL UNIVERSITY   (China)

^b FUDAN UNIVERSITY   (China)

^c JIUJIANG UNIVERSITY   (China)

Author keywords

Autism; Oxidative stress; Sulindac; Valproic acid; Wnt catenin pathway

Indexed keywords

4 HYDROXYNONENAL; ACETYLCYSTEINE; BETA CATENIN; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; NEUROPROTECTIVE AGENT; REACTIVE OXYGEN METABOLITE; SULINDAC; VALPROIC ACID; WNT PROTEIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA;

ADOLESCENT; ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; AUTISM; BRAIN CELL CULTURE; CELL VIABILITY; COMPARATIVE EFFECTIVENESS; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; FEMALE; IN VITRO STUDY; IN VIVO STUDY; LOCOMOTION; MALE; MOTOR DYSFUNCTION; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OPEN FIELD TEST; OXIDATIVE STRESS; PRENATAL DRUG EXPOSURE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING; WNT SIGNALING PATHWAY; ANIMAL; CELL CULTURE; DISEASE MODEL; DRUG EFFECTS; ENVIRONMENTAL EXPOSURE; METABOLISM; MOVEMENT DISORDERS; NERVE CELL; PREGNANCY; PRENATAL EXPOSURE; WISTAR RAT;

ANIMALS; BETA CATENIN; CELLS, CULTURED; DISEASE MODELS, ANIMAL; FEMALE; GLYCOGEN SYNTHASE KINASE 3; MATERNAL EXPOSURE; MOVEMENT DISORDERS; NEURONS; OXIDATIVE STRESS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS; RATS; RATS, WISTAR; SULINDAC; VALPROIC ACID;

EID: 84917708647     PISSN: 11073756     EISSN: 1791244X     Source Type: Journal    
DOI: 10.3892/ijmm.2014.1996     Document Type: Article

References (42)

1. Ghanizadeh A and Derakhshan N: N-acetylcysteine for treatment of autism, a case report. J Res Med Sci 17: 985-987, 2012.
2. Al-Ayadhi LY and Elamin NE: Camel milk as a potential therapy as an antioxidant in autism spectrum disorder (ASD). Evid Based Complement Alternat Med 2013: 602834, 2013.
3. Wang Z, Xu L, Zhu X, et al: Demethylation of specific Wnt/β-catenin pathway genes and its upregulation in rat brain induced by prenatal valproate exposure. Anat Rec 293: 1947-1953, 2010.
4. Zhang Y, Sun Y, Wang F, Wang Z, Peng Y and Li R: Downregulating the canonical Wnt/β-catenin signaling pathway attenuates the susceptibility to autism-like phenotypes by decreasing oxidative stress. Neurochem Res 13: 1409-1419, 2012.
5. Hall AC, Lucas FR and Salinas PC: Axonal remodeling and synaptic differentiation in the cerebellum is regulated by WNT-7a signaling. Cell 100: 525-535, 2000.
6. Chenn A and Walsh CA: Regulation of cerebral cortical size by control of cell cycle exit in neural precursors. Science 297: 365-369, 2002.
7. Brault V, Moore R, Kutsch S, et al: Inactivation of the beta-catenin gene by Wnt1-Cre-mediated deletion results in dramatic brain malformation and failure of craniofacial development. Development 128: 1253-1264, 2001.
8. Martin PM, Yang X, Robin N, et al: A rare WNT1 missense variant overrepresented in ASD leads to increased Wnt signal pathway activation. Transl Psychiatry 3: e301, 2013.
9. Atkin TA, MacAskill AF, Brandon NJ and Kittler JT: Disrupted in Schizophrenia-1 regulates intracellular trafficking of mitochondria in neurons. Mol Psychiatry 16: 122-124, 121, 2011.
10. Bošković M, Grabnar I, Terzič T, Kores Plesničar B and Vovk T: Oxidative stress in schizophrenia patients treated with long-acting haloperidol decanoate. Psychiatry Res 210: 761-768, 2013.
11. Crespi B, Stead P and Elliot M: Evolution in health and medicine Sackler colloquium: Comparative genomics of autism and schizophrenia. Proc Natl Acad Sci USA 107 (Suppl 1): 1736-1741, 2010.
12. Lemjabbar-Alaoui H, Dasari V, Sidhu SS, et al: Wnt and Hedgehog are critical mediators of cigarette smoke-induced lung cancer. PLoS One 1: e93, 2006.
13. Huang Y, Chang X, Lee J, et al: Cigarette smoke induces promoter methylation of single-stranded DNA-binding protein 2 in human esophageal squamous cell carcinoma. Int J Cancer 128: 2261-2273, 2011.
14. Hansen MB, Nielsen SE and Berg K: Re-examination and further development of a precise and rapid dye method for measuring cell growth/cell kill. J Immunol Methods 119: 203-210, 1989.
15. Pearson BL, Pobbe RL, Defensor EB, et al: Motor and cognitive stereotypies in the BTBR T+tf/J mouse model of autism. Genes Brain Behav 10: 228-235, 2011.
16. Orner GA, Dashwood WM, Blum CA, Diaz GD, Li Q and Dashwood RH: Suppression of tumorigenesis in the Apc(min) mouse: down-regulation of beta-catenin signaling by a combination of tea plus sulindac. Carcinogenesis 24: 263-267, 2003.
17. Rice PL, Kelloff J, Sullivan H, et al: Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. Mol Cancer Ther 2: 885-892, 2003.
18. Toledo EM, Colombres M and Inestrosa NC: Wnt signaling in neuroprotection and stem cell differentiation. Prog Neurobiol 86: 281-296, 2008.
19. Löscher W: Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 16: 669-694, 2002.
20. Jafarian I, Eskandari MR, Mashayekhi V, Ahadpour M and Hosseini MJ: Toxicity of valproic acid in isolated rat liver mitochondria. Toxicol Mech Methods 23: 617-623, 2013.
21. Khan S, Ahmad T, Parekh CV, Trivedi PP, Kushwaha S and Jena G: Investigation on sodium valproate induced germ cell damage, oxidative stress and genotoxicity in male Swiss mice. Reprod Toxicol 32: 385-394, 2011.
22. Wang C, Luan Z, Yang Y, Wang Z, Cui Y and Gu G: Valproic acid induces apoptosis in differentiating hippocampal neurons by the release of tumor necrosis factor-alpha from activated astrocytes. Neurosci Lett 497: 122-127, 2011.
23. Santos F, Teixeira L, Lúcio M, et al: Interactions of sulindac and its metabolites with phospholipid membranes: an explanation for the peroxidation protective effect of the bioactive metabolite. Free Radic Res 42: 639-650, 2008.
24. Goldman S, O'Brien LM, Filipek PA, Rapin I and Herbert MR: Motor stereotypies and volumetric brain alterations in children with Autistic Disorder. Res Autism Spectr Disord 7: 82-92, 2013.
25. Lemonda BC, Holtzer R and Goldman S: Relationship between executive functions and motor stereotypies in children with Autistic Disorder. Res Autism Spectr Disord 6: 1099-1106, 2012.
26. Hattier MA, Matson JL, Macmillan K and Williams L: Stereotyped behaviours in children with autism spectrum disorders and atypical development as measured by the BPI-01. Dev Neurorehabil 16: 291-300, 2013.
27. Schneider T and Przewlocki R: Behavioral alterations in rats prenatally exposed to valproic acid: animal model of autism. Neuropsychopharmacology 30: 80-89, 2005.
28. Schneider T, Turczak J and Przewlocki R: Environmental enrichment reverses behavioral alterations in rats prenatally exposed to valproic acid: issues for a therapeutic approach in autism. Neuropsychopharmacology 31: 36-46, 2006.
29. Markram K, Rinaldi T, La Mendola D, Sandi C and Markram H: Abnormal fear conditioning and amygdala processing in an animal model of autism. Neuropsychopharmacology 33: 901-912, 2008.
30. Rinaldi T, Silberberg G and Markram H: Hyperconnectivity of local neocortical microcircuitry induced by prenatal exposure to valproic acid. Cereb Cortex 18: 763-770, 2008.
31. Bass SE, Sienkiewicz P, Macdonald CJ, et al: Novel dithiolethione-modified nonsteroidal anti-inflammatory drugs in human hepatoma HepG2 and colon LS180 cells. Clin Cancer Res 15: 1964-1972, 2009.
32. Pitsikas N, Zisopoulou S and Sakellaridis N: Nitric oxide donor molsidomine attenuates psychotomimetic effects of the NMDA receptor antagonist MK-801. J Neurosci Res 84: 299-305, 2006.
33. Pitsikas N, Zisopoulou S, Pappas I and Sakellaridis N: The selective 5-HT(6) receptor antagonist Ro 04-6790 attenuates psychotomimetic effects of the NMDA receptor antagonist MK-801. Behav Brain Res 188: 304-309, 2008.
34. Mesches MH, Gemma C, Veng LM, et al: Sulindac improves memory and increases NMDA receptor subunits in aged Fischer 344 rats. Neurobiol Aging 25: 315-324, 2004.
35. Bliss TV and Collingridge GL: A synaptic model of memory: long-term potentiation in the hippocampus. Nature 361: 31-39, 1993.
36. Basselin M, Chang L, Chen M, Bell JM and Rapoport SI: Chronic administration of valproic acid reduces brain NMDA signaling via arachidonic acid in unanesthetized rats. Neurochem Res 33: 2229-2240, 2008.
37. Kern JK, Haley BE, Geier DA, Sykes LK, King PG and Geier MR: Thimerosal exposure and the role of sulfation chemistry and thiol availability in autism. Int J Environ Res Public Health 10: 3771-3800, 2013.
38. Hsieh CL, Wang HE, Tsai WJ, Peng CC and Peng RY: Multiple point action mechanism of valproic acid-teratogenicity alleviated by folic acid, vitamin C, and N-acetylcysteine in chicken embryo model. Toxicology 291: 32-42, 2012.
39. Tunali S: The effects of vitamin B6 on lens antioxidant system in valproic acid-administered rats. Hum Exp Toxicol 33: 623-628, 2013.
40. Zhang Z, Qin X, Zhao X, et al: Valproic acid regulates antioxidant enzymes and prevents ischemia/reperfusion injury in the rat retina. Curr Eye Res 37: 429-437, 2012.
41. Patel AP, John MA, Handy RD and Robert SJ: Carbon monoxide exposure in rat heart: glutathione depletion is prevented by antioxidants. Biochem Biophys Res Commun 302: 392-396, 2003.
42. Deutsch SI, Pepe GJ, Burket JA, Winebarger EE, Herndon AL and Benson AD: D-cycloserine improves sociability and spontaneous stereotypic behaviors in 4-week old mice. Brain Res 1439: 96-107, 2012.